Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in BDC therapeutics.
Synopsis
- In 2022, there will be more than 71,000 diagnosed prevalent cases of bile duct cancer across 16 pharmaceutical markets.
- There are seven marketed innovator drugs for the treatment of bile duct cancer, mostly tyrosine kinase inhibitors.
- R&D activity in bile duct cancer is robust globally, with three products in pre-registration and 16 products in Phase III development in the US, EU, Asia, and global markets.
- Institutional sponsors dominated the clinical trial development in bile duct cancer, with UK emerging as the key country for conducting Phase III trials in bile duct cancer.
- During the past 12 months, six strategic alliances and one merger and acquisition transactions involving bile duct cancer assets were successfully completed.
- Approvals expected in near future for molecules from key companies such as AstraZeneca, Otsuka and Servier.
GlobalData’s Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the BDC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BDC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Report Scope
- Abbreviations
- Key Findings
- Disease Overview
- Epidemiology Overview
- Epidemiology Overview: Diagnosed Prevalent Cases of BDC in 2022 and 2027
- Table Across the 16 major pharmaceutical markets (listed in the table below), GlobalData estimates that there will be approximately 72,000 diagnosed prevalent cases of BDC in 2022.
- Epidemiology Overview: Diagnosed Prevalent Cases of BDC in 2022 and 2027
- Treatment Guidelines
- Marketed Drugs Assessment
- Marketed Drugs – Leading Marketed Drugs in BDC
- Marketed Drugs – Overview by Mechanism of Action
- Marketed Drugs – Overview by Route of Administration
- Marketed Drugs – Overview by Molecule Type
- Marketed Drug Profile: AstraZeneca's Imfinzi
- Marketed Drug Profile: Roche's Rozlytrek
- Marketed Drug Profile: Otsuka's Lytgobi
- Marketed Drug Profile: QED Therapeutics' Truseltiq
- Marketed Drug Profile: Servier's Tibsovo
- Marketed Drug Profile: Merck's Keytruda
- Marketed Drug Profile: Incyte's Pemazyre
- Pricing and Reimbursement Assessment
- Marketed Drugs – Manufacturer Price (in $/dose) for Oral Formulations in BDC
- Marketed Drugs – Manufacturer Price (in $/dose) for Intravenous Formulations in BDC
- Marketed Drugs – Manufacturer Price ($/dose)
- Table Marketed Drugs – Manufacturer Price ($/dose)
- Marketed Drugs – Time to Pricing and Reimbursement for Durvalumab
- Marketed Drugs – Time to Pricing and Reimbursement for Entrectinib
- Marketed Drugs – Time to Pricing and Reimbursement for Pembrolizumab
- Marketed Drugs – Time to Pricing and Reimbursement for Pemigatinib
- Pipeline Drugs Assessment
- Pipeline Drugs Overview – Pre-registration and Phase III Pipeline Drugs in BDC
- Pipeline Drugs – Overview by Development Stage
- Pipeline Drugs – Overview by Mechanism of Action
- Pipeline Drugs – Overview by Route of Administration
- Pipeline Drugs – Overview by Molecule Type
- Pipeline Drugs – Drug-Specific Phase Transition Success Rate and Likelihood of Approval in BDC
- Pipeline Drugs – Phase Transition Success Rates and Likelihood of Approval in Oncology and in BDC
- Clinical Trials Assessment
- Clinical Trials in BDC – Historical Overview
- Clinical Trials in BDC – Overview by Phase
- Clinical Trials in BDC – Overview by Status
- Clinical Trials in BDC – Overview by Phase for Ongoing and Planned Trial
- Clinical Trials in BDC – Trials with a Virtual Component
- Clinical Trials in BDC – Geographic Overview
- Clinical Trials in BDC – Single-Country and Multinational Trials by Region
- Clinical Trials in BDC – Top 20 Sponsors with Breakdown by Phase
- Clinical Trials in BDC – Top 20 Sponsors with Breakdown by Status
- Clinical Trials in BDC – Overview by Endpoint Status
- Clinical Trials in BDC – Overview by Race and Ethnicity
- Clinical Trials in BDC – Enrollment Data
- Table Enrollment data for Phase II trials in BDC (including Phase II and II/III)
- Table Enrollment data for Phase III trials in BDC (including Phase III and III/IV)
- Clinical Trials in BDC – Overview of Sites by Geography
- Clinical Trials in BDC – Top 20 Countries for Trial Sites
- Clinical Trials in BDC – Top 20 Sites Globally
- Clinical Trials – Feasibility Analysis: Geography Overview
- Table The top countries where GlobalData recommends running a Phase III trial in BDC include UK, Japan, South Korea, Iran, Austria, China, France, and the US, among others.
- Clinical Trials – Feasibility Analysis: Benchmark Models for BDC
- Deals Landscape
- Deals Landscape – Mergers, Acquisitions, and Strategic Alliances in BDC by Region
- Deals Landscape – Recent Mergers, Acquisitions, and Strategic Alliances in BDC
- Commercial Assessment
- Commercial Assessment – Key Market Players in BDC
- Future Market Catalysts
- Future Market Catalysts – Upcoming Market Catalysts in BDC
- Appendix
- Methodology
- Methodology – Sales Forecasts
- Methodology – Pricing and Reimbursement
- Methodology – Phase Transition Success Rate and Likelihood of Approval Analysis
- About the Authors
- Contact Us
- Contact Us – A Global Network of Offices
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook